Since 1993, Nellcor™ pulse oximetry technology has been utilized on more than 33,000 newborns spanning five separate clinical studies evaluating the use of pulse oximetry for critical congenital heart disease screening.([FOOTNOTE=Hoke, T.R., et al., Oxygen saturation as a screening test for critical congenital heart disease: a preliminary study. Pediatr Cardiol, 2002 Jul-Aug. 23(4): p. 403-9.],[ANCHOR=],[LINK=]),([FOOTNOTE=Reich, J.D., et al., The use of pulse oximetry to detect congenital heart disease. J Pediatr, 2003 Mar. 142(3): p. 268-72.],[ANCHOR=],[LINK=]),([FOOTNOTE=Arlettaz, R., et al., The contribution of pulse oximetry to the early detection of congenital heart disease in newborns. Eur J Pediatr, 2006 Feb. 165(2): p. 94-8.],[ANCHOR=],[LINK=]),([FOOTNOTE=Sendelbach, D.M., et al., Pulse oximetry screening at 4 hours of age to detect critical congenital heart defects. Pediatrics, 2008 Oct. 122(4): p. e815-20.],[ANCHOR=],[LINK=]),([FOOTNOTE=Walsh, W., Evaluation of pulse oximetry screening in Middle Tennessee: cases for consideration before universal screening. J Perinatol, 2011 Feb. 31(2): p. 125-9.],[ANCHOR=],[LINK=])
Using Nellcor™ pulse oximetry screening has been shown to be a simple and economical tool to aid healthcare providers in CCHD screening.6 The convenient Nellcor™ portable SpO2 patient monitoring system, PM10N, delivers accurate, reliable SpO2 and pulse rate values even during patient motion, and can communicate this information in trend report for data analysis. The ability to accurately measure O2 saturation and heart rate through motion is necessary for an effective CCHD screening. The portability of the system, allows for easy access to the monitor by clinicians and the opportunity for tandem screenings. This enhanced functionality provides information and accuracy clinicians can rely on for this important screening.